MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

MacroGenics (MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025.

Rhea-AI Summary

MacroGenics (MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's management team will deliver a presentation on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. Interested parties can access the presentation webcast through the Investor Relations section of MacroGenics' website, specifically under the "Events & Presentations" tab. The webcast recording will remain available on the company's website for 30 days after the event.

Argus Session date unavailable

-0.66% session move Open Argus

Details

News Market Reaction – MGNX

The recorded move for MGNX in the trading session of this news was -0.66%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46^th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Contacts:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com 

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is MacroGenics (MGNX) presenting at the Goldman Sachs Healthcare Conference 2025?

MacroGenics will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.

How can I watch MacroGenics' (MGNX) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be accessed through the 'Events & Presentations' section in MacroGenics' Investor Relations website at http://ir.macrogenics.com/events.cfm

How long will MacroGenics' (MGNX) Goldman Sachs Conference presentation be available online?

MacroGenics will maintain an archived replay of the webcast on its website for 30 days after the presentation.

What is MacroGenics' (MGNX) main business focus?

MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for cancer treatment.